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Brain and steroids: a long history of love
ANDREA RICCARDO GENAZZANI,  NICOLA PLUCHINO 
Abstract
In the aftermath of the Women's Health Initiative studies, both the clinical and basic science communities had
to sort out divergent results among experimental findings, observational data and randomized controlled trials
in order to establish a shared analysis. The scientific community formally debates the role of different HRT
formulations, hormone doses, time of treatment initiation since the menopause and the age of treated women.
Basic scientists demonstrated that the multiple neuroprotective effects of estrogen on brain cells may induce
a differential biological response according to the time of treatment. Progesterone (but not all synthetic pro-
gestins) also has pivotal neuroactive functions in animal models of reproductive aging. Additionally, epidemio-
logical surveys provide information regarding the detrimental role of hypogonadism on mental well-being.
The present article briefly summarizes current evidence supporting the neuroactive role of estrogen, with refe-
rence to the clinical finding sustaining the intriguing hypothesis of the early female brain senescence as a highly
responsive period to estrogen treatment.
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Introduction 
Sex steroids hormones play fundamental roles in the
development and function of central nervous system
(CNS). Estrogens, progestins and androgens are able to
induce several effects in brain areas of the central
nervous system (CNS), through the binding with specific
receptors. The action of sex hormones is not limited to
the regulation of endocrine functions and mating beha-
vior: the identification of estrogen, progestin and andro-
gen receptors outside the classical CNS regions, such as
pituitary and hypothalamus, justifies their role in con-
trolling different brain functions [1].
These findings highlight the importance of sex ste-
roids in development and regulation of the CNS. Marked
differences are found in the structure and in the function
of brain of male and female animals and humans [2].
Indeed, in humans and in rats several areas of the brain
show gender dimorphism, as indicated by differences in
structure (such as different numbers of cells in specific
areas). The different organization of brain areas in males
and females appears to be largely dependent on the
action of sex steroid hormones as demonstrated by the
differential expression of steroid receptors in sexually
dimorphic nuclei [3]. These “organizational/develop-
mental” effects are permanent and are acting during de-
velopment, mainly in the fetal-neonatal period when
estrogens and aromatizable androgens modulate neuro-
nal development and the formation of neuronal circuits.
As a result, several areas of the CNS become sexually
differentiated. This is also suggested by the evidence
that the levels of circulating and locally-produced ste-
roids control the structure and activity of sexually di-
morphic nuclei. Therefore, exogenous sex steroids could
cause differences in the structure/function of specific
brain areas with measurable clinical effects. Although
abundant morphological and functional evidence exists
for sex differences in brain development, much less is
known regarding the underlying developmental mecha-
nisms that direct these differences [4]. Since neurons
are limited in their proliferative life and there is con-
siderable programmed cell death after birth, the effect
of steroids appears to involve regulation of neural cell
kinetics and apoptosis. Sexual dimorphism is also pre-
sent in other cellular compartments such as the glia, and
the sex steroid-related developmental differences seen
in both animals and humans are real and complex [5].
Gender differences show up, among others, in dendritic
structure, organization of the neuronal membrane, neu-
ronal connectivity patterns, as well as in opiate receptor
numbers [6]. 
Gonadal steroids, brain through the lifespan 
Brain plasticity is most apparent during early deve-
lopment as formation of the nervous system but it con-
tinues through puberty, reproduction and adult life
[5, 7]. These “activational/neuroplasticity” effects are
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transient and fluctuate considerably as the hormonal
milieu changes then affecting almost potentially every
aspect of brain physiology in different biological phase.
Estrogen-induced synaptic plasticity is well seen during
puberty and seasonal changes as well as during the
ovarian cycles. Estrogen appears to be important for the
regulation and maintenance of network integrity of seve-
ral brain areas related to cognition [8]. In addition to
changes in the cortex accompanying cognitive tasks
estrogen regulates the anatomy and connectivity of the
hippocampus and associated structures [9, 10]. In post-
menopause, neurotransmitters, neuropeptides and
neurosteroids undergo important changes as a conse-
quence of the failure of gonadal hormone production, at
a time when many CNS activities deteriorate, parti-
cularly those associated with hippocampal functions such
as memory, attention, cognition and autonomic control
[11]. This neuroendocrinological aging process repre-
sents a unique opportunity to investigate the actions of
gonadal hormones on their specific receptors in the Ner-
vous System.
One of the most exciting areas of research in
women’s health over the past 10 yr involves our growing
appreciation that estrogens play important neurotrophic
and neuroprotective roles during adulthood. This brings
new meaning to the potential impact of the prolonged
postmenopausal hypoestrogenic state on learning and
memory and the potential increased vulnerability of
aging women to brain injury and neurodegenerative
diseases. The increase in female life expectancy during
the past century has meant that women now live one-
third of their lives beyond cessation of their ovarian
function. This evolution in demography has increased
the need for the development of new therapeutical
strategies to promote successful aging, defined as low
probability of disease, high cognitive and physical capa-
city and active engagement in life. Because changes in
the aging nervous system are subtle, it may be possible
to reverse them and to improve cognitive performance
by pharmacological treatments. The administration of
steroids may be particularly promising in this regard: (a)
they play an important role in the functioning of the
central and peripheral nervous system (CNS and PNS);
(b) some steroids have neuroprotective effects; (c) the
levels of some neuroactive steroids markedly decrease
with age; and (d) unconjugated steroids easily cross the
blood-brain barrier and rapidly accumulate throughout
the brain. 
Estrogen receptors (ERs) are found in both the
hippocampus and frontal lobes which subserve verbal
memory, working memory and retrieval. It was rea-
sonable to hypothesize that this hormone might play an
important protective role against the deterioration in
these cognitive functions that occur with normal aging.
It is indeed now well recognized that the functions of
gonadal and adrenal steroid hormones go far beyond
reproduction and that they regulate vital neuronal and
glial functions by a variety of mechanisms of action [12].
In addition, some steroids, named “neurosteroids,” can
be synthesized within the nervous system by both neu-
rons and glial cells that are produced in concentrations
high enough to exert paracrine effects. Synthesis of
brain neurosteroids declines with age, during stressful
conditions (including major depression, chronic psy-
chological stress), and in chronic inflammatory and neu-
rodegenerative diseases. Recent reports associate the
decrease of brain neurosteroids to neuronal dysfunction
and degeneration. Stimulation of their synthesis offers
new therapeutical possibilities to counteract brain-aging
process.
Menopause as a model to understand the role of
sex steroids in the brain
Epidemiologic data suggest an increased incidence
and prevalence of depressive symptoms in women in
their mid-40s and again between the ages of 55 and 64
years. Estrogen deficiency has been suggested as a cau-
se of this increased prevalence of depressive disorders
in women and the menopausal transition appears to be
a period of vulnerability to depressive symptoms with or
without a history of depression. It has demonstrated that
psychological distress appears to increase in early peri-
menopause compared with premenopause and vasomo-
tor symptoms further increase the risk of psychological
distress. The Study of Women Across the Nation
(SWAN), reported that more than 40% of participants
had increased irritability, nervousness, mood changes
and dysphoric mood in the previous 2 weeks in early
perimenopause compared with premenopause [13-14].
Additionally, 14.3% reported feeling depressed 6 or
greater days within the past 2 weeks. Considering that
the perimenopause can last up some years, the risk of
developing depression during the perimenopause can be
as high as 14 times that of premenopausal women. De-
pression is the second leading cause of disability in
developed countries and the potential burden of illness
experienced by depressed perimenopausal women is
significant. In particular, women experiencing long tran-
sitions to menopause were at greater risk of depression
than those having short transitions. The association
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between a long perimenopause and depression appeared
to be explained by increased menopausal symptoms
rather than by the menopause status: the presence of va-
somotor symptoms appears to be associated with a high-
er prevalence of depressed mood, and anxiety is a signi-
ficant predictor of hot flashes among women in the late
reproductive years.
Additionally, Brown et al. in a population-based
cross-sectional study of 639 women, found significant
links between depressive symptoms and several meno-
pausal symptoms including hot flashes, sleep disturban-
ce, irritability (the Harvard Study of Moods and Cycles).
In particular, Brown et al., found a two-fold increase in
the risk of developing depressive symptoms during the
perimenopause among women who nocturnal hot flashes
without a history of depression [14] experience of hot
flashes at baseline was marginally significantly more fre-
quent among women who reported severe depressive
symptoms during an 8-year follow up as compared to
women who did not exhibit mood symptoms during the
follow up period. Additionally, participants with severe
mood symptoms during follow up were 2.16 times more
likely to report hot flashes at the same visit. 
The effect of the menopausal transition and sex
hormones on anxiety disorders is much less studied than
depression, despite the finding that nearly half women
during the climacterium experience anxiety and stress
symptoms. Data from the Penn Ovarian Aging Study
(POA) strongly support that anxiety was associated with
hot flashes in a community-based cohort of African
American and white women. The most anxious women
had the most severe and most frequent vasomotor symp-
toms. The relationship between hot flashes and anxiety
persisted after adjusting for menopause transition stage,
depressed mood symptoms, smoking, body mass index,
estradiol, age, race, and time since the baseline measu-
res in the study.
Interesting data on the relationship between sex
steroids, menopause and mood disorders come from the
Mayo Clinic Cohort Study of Oophorectomy and Aging
by Rocca et al. [16]. The study involves a population-
based cohort of women residing in Olmsted County, MN,
who underwent oophorectomy before the onset of me-
nopause for a non cancer indication from 1950 to 1987.
For a median follow-up period of 24 years, the risk of
anxiety symptoms increased significantly in women who
underwent bilateral oophorectomy compared with refe-
rent women (adjusted HR, 2.29; 95% CI, 1.33-3.95). The
increased risk of anxiety symptoms was particularly evi-
dent among women who underwent surgery before the
age of 48 years (adjusted HR, 2.66; 95% CI, 1.39-5.09).
Bilateral oophorectomy was also a risk factor for depres-
sion diagnosed by a physician (adjusted HR, 1.54; 95%
CI, 1.04-2.26) [15-22].
Neurobiologically, both vasomotor symptoms and
mood disorders are regulated by the monoamine neuro-
transmitters serotonin, norepinephrine and dopamine.
Thus, dysregulation of these systems can lead to depres-
sion when that dysregulation occurs within brain areas
deputed to mood control (prefontral cortex, limbic
system) and can lead to vasomotor symptoms when the
dysregulation involves the hyphotalamic centers deputed
to thermoregulatory body mechanism. 
In the previous paragraph we evaluate the positive
neurobiological effect that estrogens have in the brain
monoamine turnover; thus it is theoretically possible
that treating vasomotor symptoms using estrogens could
prevent depressive symptoms in vulnerable women. In
addition, remission from symptoms of mood disorders
such as anxiety, depression and sleep disturbance with-
out a full reduction of vasomotor symptoms could be
a signal that estrogen fluctuation in the brain continues
to create vulnerability for mood disorders relapse [23].
A role of neurosteroids in central menopausal sym-
ptoms has been also recently hypothesized. Menopause
transition is associated with decreased allopregnanolone
levels, mainly due to reduced ovarian synthesis of pro-
gesterone, supporting its role in the mood disorder phy-
siology during the climacterium. Indeed low circulating
allopregnanolone levels are associated with the onset of
depression and anxiety during the reproductive aging. 
In postmenopausal women, HRT is able to modify
circulating levels of neurosteroids, determining an in-
crease in allopregnanolone levels and a decrease in
DHEA. These data indicate a main role for these com-
pounds as neuroendocrine mediators of the effects of
estrogens on the CNS and the effect exerted by HRT on
allopregnanolone levels might be related to the anxio-
lytic and sedative effects of HRT in menopausal women.
However synthetic progestins available in the clinical
setting have different effects on central neurosteroido-
genis supporting the concept that synthetic progestins
may show differential activity on brain biology. This fea-
ture involves the synthesis of brain allopregnanolone and
the specific activity on GABA-A receptor of progestins,
rather than the activation of PRs [24]. 
Certainly, the study of neurosteroids in menopausal-
related mood changes may offer several new perspec-
tives to understand the brain pathophysiology of the
climacterium and the hormonal strategies to cure it. 
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Fig. 1. Sex hormones are directly involved in the  brain gender
differentiation processes; gender cognitive and behavioural
actions are due to the influences of estrogens and androgens
on neuronal development during fetal-neonatal life and on
 circuits activation during adulthood
Fig. 2.  Neurosteroids levels fluctuate throughout the lifespan.
During intrauterine life neurosteroid participate in the control
of neuronal survival and apoptosis and on the neuronal stem
cell differentiation. During childhood and adult brain neuro-
steroids reach elevated values to protect the CNS from endo-
genous and esogenous neurotoxic factors and to promote
neurogenesis. During aging neurosteroids levels progressively
 decrease leaving brain unprotected from neurotoxic factors
Fig. 3. Brain vulnerability throughout the lifespan
Menopause and cognitive decline: early symptoms
for an early treatment
The detection of early neural markers of brain aging
and cognitive dysfunction is one of the main challenges
during the climacterium and the early postmenopause
and the degree of cognitive vitality during the aging pro-
cess could depend on early clinical interventions. 
The evidence that estrogen has several neuropro-
tective effects brings new meaning to the potential im-
pact of the prolonged post-menopausal hypoestrogenic
state on learning and memory and the potential in-
creased vulnerability of ageing women to brain injury
and neurodegenerative diseases.  
Although the apparent dichotomy between the bene-
ficial actions of E2 on the brain of experimental animals
(see previous paragraphs) and report from randomized
controlled trials in women (mainly WHI) could be great
conundrum, a critical analysis of clinical data robustly
supports the neurotrophic effect of estrogen. 
Results from the Mayo Clinic Cohort Study of
Oophorectomy and Aging provide the degree of the long-
term influence that sex steroid deprivation has on cog-
nitive vitality. In particular women who underwent either
unilateral or bilateral oophorectomy had an increased
risk of cognitive impairment or dementia compared with
women with natural menopause (adjusted HR, 1.46; 95%
CI, 1.13-1.90). In another study, the risk of Parkinson
disease was higher in women who underwent either uni-
lateral or bilateral oophorectomy (adjusted HR, 1.68;
95% CI, 1.06-2.67) [19]. In both studies, a younger age
at menopause was associated with increased risk of neu-
rological impairment. In particular, Rocca et al. observed
significant linear trends of increasing risk for either
outcome with younger age at oophorectomy. Estrogen
deficiency is the initial step in a chain of causality that
determined the increased risk of cognitive impairment
or dementia. In support of a neuroprotective effect of
estrogen, women who underwent bilateral oophorectomy
before age 49 years but were given estrogen treatment
until at least age 50 years had no increased risk.
Epidemiological surveys prospectively monitoring
women as they progress through the menopause tran-
sition have suggested that self reports of decreased con-
centration and poor memory are frequent accompani-
ments of this phase of life and the postmenopause.
In the Study of Women's Health Across the Nation
(SWAN), more than 40% of perimenopausal and post-
menopausal women endorsed forgetfulness on a symp-
tom inventory compared with 31% of premenopausal
women [20]. In the Seattle Midlife Women's Health
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Study, approximately 62% of midlife women reported an
undesirable change in memory [21]. 
Maki at al. investigated the relationship between
objective measures of hot flashes and one particular
domain, verbal episodic memory, in a sample of midlife
women. In particular, the presence of objective hot
flashes is negative predictor of verbal memory in midlife
women with moderate to severe vasomotor symptoms.
This relationship appears to be primarily due to night-
time rather than daytime hot flashes supporting the
concept that hot flashes and sleep disturbances are sign
of brain vulnerability to sex steroid withdrawal with a ne-
gative impact of cognition [22]. Hypothalamic and HPG
axis senescence induces vasomotor symptoms and hypo-
gonadism that could trigger menopause-related mental
decline in other brain areas years before deficits in
learning and cognition would normally start to become
evident. The epidemiological data on the neuroprotec-
tive effects of estrogen-base therapy were reviewed by
Leblanc and colleagues: women who were symptomatic
from the menopause had improvement in verbal memo-
ry, vigilance, reasoning and motor speed when given
HRT. The same meta-analysis of observational studies
examining HRT and cognitive function also suggest
a significant reduction in the risk of AD among women
who have ever used HRT [23]. In particular, the strong-
est evidence for an association between HRT and Alzhei-
mer disease comes from 2 cohort studies: the Manhat-
tan Study of Aging [24] and The Baltimore Longitudinal
Study of Aging [25]. The two prospective cohort studies
that reported a significantly reduced risk of AD in estro-
gen users is particularly compelling because they avoid
both recall and prescribing-practice bias. In the Italian
Longitudinal Study on Aging, ERT was associated with
a reduced prevalence of AD in 2816 women (OR, 0.24;
95% CI, 0.07-0.77) [26]. Analysis of observational data
from the Cache County Study suggested a reduction in
the risk of AD for past HRT users for 3-10 years. In the
same study, the ”excess” risk of AD when compared
with age-equivalent men disappeared among women who
received HRT for more than 10 years [23-33].
In conclusion, the majority of studies and meta-ana-
lyses evidencing cognitive benefits during HRT analyze
young symptomatic postmenopausal women, supporting
the concept of the ”window of opportunity” for estrogen
neurotrophic effects.
Conclusion and perspectives
In the aftermath of the WHI studies, both the clini-
cal and basic science communities were forced to try and
make sense of these divergent results and take a careful
look at the nature of HRT formulations and variables,
such as the time of initiation of treatment and the age of
the subjects.
Basic scientists demonstrated that multiple neuro-
protective effects of estrogen on brain cells may have
a time bias and that progesterone (but not all synthetic
progestins) has also pivotal neuroactive functions in ani-
mal models of reproductive aging.  
Furthermore epidemiological surveys add informa-
tion on the detrimental role of hypogonadism on metal
well-being stratifying findings for patient characteristics
and symptoms and for time of steroid withdrawal and
subsequent exposition.   
All these analysis could reconcile finding from basic
research and clinical data supporting the concept for
a positive role of sex steroids in mental well-being and as
powerful therapeutic tool for those women for whom
ovarian steroids are critically involved in the regulation of
affective, cognitive, and behavioral adaptation to aging.
Evidences sustain the intriguing hypothesis that
early symptoms of hypothalamic and HPG axis senescen-
ce (i.e. vasomotor symptoms) might indicate the vulne-
rability of other brain areas (i.e. amygdale, hippocampus
and prefrontal cortex) to develop future dysfunctions
during the aging process. The identification of the early
role for estrogen deficiency in the chain of causality that
determined the lifelong increased risk of mood disorders
and cognitive impairment in vulnerable women, supports
solidly the early temporal initiation of estrogen therapy.
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